Precigen News

Precigen to Present Late-breaking Abstract for Pivotal Phase 2 Study Data for PRGN-2012 AdenoVerse Immunotherapy for the Treatment of Patients With Recurrent Respiratory Papillomatosis at the 2024 ASCO Annual Meeting

Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives ...

PR NewswireApr 24 10:20 ET

AnaptysBio Names Thomas Smart as CEO >ANAB

AnaptysBio Names Thomas Smart as CEO >ANAB

Dow JonesApr 24 09:01 ET

Express News | Actym Therapeutics Appoints Thomas Smart as CEO

Moomoo 24/7Apr 24 09:00 ET

Precigen and Recurrent Respiratory Papillomatosis Foundation to Hold Inaugural International RRP Awareness Day on June 11th

– Inaugural multi-stakeholder event on June 11th (6/11) will raise awareness and bring together individuals living with RRP, caregivers, clinicians, and government officials – – RRP is a rare, HP

PR NewswireMar 28 16:05 ET

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN), Cronos Group (CRON) and Marinus (MRNS)

TipRanksMar 26 08:10 ET

Precigen Cut to Underweight From Neutral by JP Morgan

Precigen Cut to Underweight From Neutral by JP Morgan

Dow JonesMar 22 12:22 ET

J.P. Morgan Cuts Precigen to Underweight, Cites Burn Rate

Seeking AlphaMar 22 11:10 ET

Precigen's Financial Tightrope: Balancing R&D Investment and Funding Challenges Amid Economic Headwinds

TipRanksMar 21 02:02 ET

Precigen Price Target Maintained With a $14.00/Share by JMP Securities

Precigen Price Target Maintained With a $14.00/Share by JMP Securities

Dow JonesMar 20 09:51 ET

Express News | HC Wainwright & Co. Reiterates Buy on Precigen, Maintains $6 Price Target

Moomoo 24/7Mar 20 06:52 ET

Precigen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/20/2024 328.57% HC Wainwright & Co. → $6 Reiterates Buy → Buy 08/10/2023 328.57% HC Wainwright & Co. →

BenzingaMar 20 06:51 ET

Buy Rating Affirmed on Precigen Amid Promising PRGN-2012 Clinical Progress and Financial Stability

TipRanksMar 20 06:17 ET

Q4 2023 Precigen Inc Earnings Call

Yahoo FinanceMar 20 06:04 ET

Analysts Offer Insights on Healthcare Companies: Precigen (PGEN) and Taysha Gene Therapies (TSHA)

TipRanksMar 20 00:40 ET

Earnings Call Summary | Precigen(PGEN.US) Q4 2023 Earnings Conference

The following is a summary of the Precigen, Inc. (PGEN) Q4 2023 Earnings Call Transcript:Financial Performance:Data not provided.Business Progress:Data not provided.More details: Precigen IRTips: This

moomoo AIMar 19 20:54 ET · Conference Call

Precigen Inc (PGEN) Reports Full Year 2023 Financial Results

Yahoo FinanceMar 19 17:31 ET

Recap: Precigen Q4 Earnings

Precigen (NASDAQ:PGEN) reported its Q4 earnings results on Tuesday, March 19, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsPrecigen missed estimated earnings by -

BenzingaMar 19 16:25 ET

Precigen Gives Business Updates, Significant Progress Made In The Development Of The PRGN-2012 Adenoverse Immunotherapy For The Treatment Of RRP; Plans To Submit A BLA Under An Accelerated Approval Pathway In 2H Of 2024

– Significant progress made in the development of the PRGN-2012 AdenoVerse immunotherapy for the treatment of RRP; Precigen plans to submit a BLA under an accelerated approval pathway in the second

BenzingaMar 19 16:11 ET

Precigen EPS $(0.39) Vs $(0.40) YoY; Cash, Cash Equivalents, Short-Term And Long-Term Investments Totaled $62.9M As Of December 31, 2023

Full Year 2023 Financial Results Compared to Prior Year PeriodResearch and development expenses increased $1.4 million, or 3.1%, compared to year ended December 31, 2022. Salaries, benefits, and other

BenzingaMar 19 16:10 ET

Precigen GAAP EPS of -$0.39 Misses by $0.31, Revenue of $6.23M Beats by $4.53M

Seeking AlphaMar 19 16:09 ET